Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 26 of 26 publications.

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772

Danese S, Kamble P, Yang J, Le Moine JG, Khan S, Hawe E, Agboton C, Wang S, Irving PM. Systematic literature review and meta-analysis: real-world mucosal healing in Vedolizumab-treated patients with Crohn's disease. GastroHep. 2022 Feb 16. doi: 10.1155/2022/6975416

Danese S, Kamble P, Yang J, Le Moine JG, Khan S, Hawe E, Agboton C, Wang S, Irving PM. Vedolizumab rates of mucosal healing in Crohn's disease: a systematic literature review and meta-analysis of real-world data. Presented at the 2021 Digestive Disease Week Virtual Conference; May 23, 2021.

Danese S, Pravin K, Yang J, Le Moine J, Khan S, Hawe E. Vedolizumab rate of mucosal healing in Crohn's disease: a systematic literature review and meta-analysis of real-world data. Poster presented at the 2021 Virtual Digestive Disease Week (DDW) Conference; May 21, 2021.

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. In reply: Network meta-analyses are not about a single treatment but about sets of regimens. Clin Ther. 2019 Jan;41(1):188-90. doi: 10.1016/j.clinthera.2018.11.011

Le Moine JG, Hawe E, Abeysinghe S. Network meta-analysis in the presence of non-proportionality: a review of NICE submissions. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018 Mar;40(3):480-94. doi: 10.1016/j.clinthera.2018.01.014

Maiese E, Graham CN, Hawe E, Le Moine JG. Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma. Poster presented at the 2018 ASCO Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; p.e20037. doi: 10.1200/JCO.2018.36.15_suppl.e20037

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711

Ainsworth CM, Vickers AD, Le Moine J. Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A767. doi: 10.1016/j.jval.2017.08.2189

Maiese EM, Le Moine JG, Ainsworth C, Ahdesmaki O, Hawe E. Comparative efficacy of multiple myeloma therapies for treatment of first relapse: a systematic literature review and network meta-analysis. Poster presented at the 2017 ASCO Annual Meeting; June 5, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).

Le Moine J, Abeysinghe SS. Comparison of Bayesian network meta-analyses in a WinBUGS and SAS framework. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A393.

Abeysinghe SS, Le Moine JG, Margulis AV, Mauskopf JA. Frequentist and Bayesian meta-analysis of risk factors for respiratory syncytial virus hospitalization in preterm infants. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A174. doi: 10.1016/j.jval.2016.03.1458

Le Moine JG, Fiestas Navarrete L, Katumba K, Launois R. Psychometric validation of the 14 items chronic venous insufficiency quality of life questionnaire (CIVIQ-14): confirmatory factor analysis. Eur J Vasc Endovasc Surg. 2016 Feb;51(2):268-74. doi: 10.1016/j.ejvs.2015.08.020.

Launois R, Le Moine J, Uzzan B, Fiestas Navarette LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical andguaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):978-89. doi: 10.1097/MEG.0000000000000160

Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988

Launois R, Uzzan B, Le Moine JG, Fiestas Navarrete L, Benamouzig R. Systematic review and bivariate/HSROC meta-analysis of immunochemical and guaiac fecal occult blood tests for colorectal cancer screening. Poster presented at the 2014 Digestive Disease Week; May 2014. Chicago, IL.

Le Moine JG, Katumba KR, Launois R. Structural validation of the chronic venous insufficiency questionnaire-14 (CIVIQ-14): a confirmatory factor analysis. Poster presented at the International Society for Pharmacoeconomics and Outcome Research 16th Annual European Congress; November 2, 2013. Dublin, Ireland.

Launois R, Le Moine JG, Lozano FS, Mansilha A. Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure. Qual Life Res. 2012 Aug;21(6):1051-8. doi: 10.1007/s11136-011-0008-3

Launois R, Le Moine JG, Huynh MT. Mixed treatment comparison, cost-effectiveness and budget impact analysis in the treatment of rheumatoid arthritis after failure of DMARD therapy: a comprehensive decision analytical modelling. Poster presented at the International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting; June 2, 2012. Washington, DC.

Le Moine JG, Launois R. Mixed treatment comparison, cost-effectiveness analysis and budget impact model in the treatment of rheumatoid arthritis after failure of conventional DMARD therapy using comprehensive Bayesian decision analytical modelling. Presented at the 3rd Joint CES/HESG Workshop; January 11, 2012. Aix-en-Provence, France.

Launois R, Le Moine JG, Huynh MT, Boissier MC. Analyse de l'impact budgétaire de la prise en charge de la polyarthrite rhumatoïde en 1ère, 2ème et 3ème ligne de traitement, après échec d'un traitement de fond. Presented at the French Society of Rheumatology 24th Annual Congress; December 11, 2011. Paris, France.

Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, Michel M, Eckert L, Launois R, Godeau B. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011 Apr;90(4):441-6. doi: 10.1007/s00277-010-1087-x

Launois R, Le Moine JG, Huynh MT, Boissier MC. Efficacité et tolérance des traitements de la polyarthrite rhumatoïde étudiés par méta-analyse hiérarchique bayésienne: combinaison simultanée des résultats relevés dans les essais randomisés et les études observationnelles avec groupe controle. Presented at the French Society of Rheumatology 23rd Annual Congress; November 28, 2010. Paris, France.